400-859-2883
Your location:Home >News center >Industry News

Industry News

11-302021

Sitagliptin - First In Class DPP4 Inhibit…

Sitagliptin, the first oral DPP-4 inhibitor to be marketed for treating Type 2 Diabetes

Sitagliptin - First In Class DPP4 Inhibitor for Type 2 Diabetes
11-202021

What Are PEG Linkers and Their Applicatio…

Learn more detailes about PEG linkers and its applications in pharmaceutical field.

What Are PEG Linkers and Their Applications?
11-162021

Ten Most Popular Anti-cancer Drugs In 202…

In view of the complexity of cancer treatment and peoples needs, the market prospects of anti-tumor drugs are broad. Many pharmaceutical and biotechnology companies have stepped up research a…

Ten Most Popular Anti-cancer Drugs In 2021
08-282021

Antibody-Drug Conjugates for Cancer Thera…

Antibody-drug conjugates (ADCs) are a rapidly evolving class of anticancer therapeutics consisting of antibodies attached to potent cytotoxic drugs via chemical linkers.

Antibody-Drug Conjugates for Cancer Therapy - Prospects and Challenges
05-112021

CDK4/6 Inhibitors for Treatment of Advanc…

There are three CDK4/6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib approved by FDA to treat Advanced Breast Cancer.

CDK4/6 Inhibitors for Treatment of Advanced Breast Cancer